Clinical trial
Dyskinesia in Parkinson's Disease (Study P04501)
NCT00406029 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00406029 |
|---|---|
| Title | Dyskinesia in Parkinson's Disease (Study P04501) |
| Official title | A Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson Disease, Movement Disorders, Central Nervous System Diseases, Neurodegenerative Diseases, Brain Diseases |
| Intervention type | Drug |
| Interventions | Preladenant, Placebo, L-dopa, Other Parkinson's Disease treatments |
| Enrollment | 253 |
| Start date | Nov 20, 2006 |
| Primary completion | Oct 5, 2008 |
| Completion | Nov 3, 2008 |
| First posted | Dec 4, 2006 |
| Last update posted | Nov 9, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: